MX2020010110A - Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos. - Google Patents

Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos.

Info

Publication number
MX2020010110A
MX2020010110A MX2020010110A MX2020010110A MX2020010110A MX 2020010110 A MX2020010110 A MX 2020010110A MX 2020010110 A MX2020010110 A MX 2020010110A MX 2020010110 A MX2020010110 A MX 2020010110A MX 2020010110 A MX2020010110 A MX 2020010110A
Authority
MX
Mexico
Prior art keywords
binding agents
drug conjugates
monoclonal binding
cmet monoclonal
cmet
Prior art date
Application number
MX2020010110A
Other languages
English (en)
Inventor
Marco Gymnopoulos
Roland Newman
Julia Coronella
Ryo Fujita
Vincent Blot
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2020010110A publication Critical patent/MX2020010110A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Aquí se presentan agentes de unión de cMET monoclonales novedosos que son conjugados a toxinas de pirrolobenzodazepina, una composición de los mismos y usos de los mismos para el tratamiento de cáncer.
MX2020010110A 2018-03-28 2019-03-27 Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos. MX2020010110A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862649078P 2018-03-28 2018-03-28
PCT/JP2019/013345 WO2019189453A1 (en) 2018-03-28 2019-03-27 DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2020010110A true MX2020010110A (es) 2020-11-06

Family

ID=68059106

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010110A MX2020010110A (es) 2018-03-28 2019-03-27 Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos.

Country Status (14)

Country Link
US (1) US20210163604A1 (es)
EP (1) EP3774923A4 (es)
JP (2) JP7177848B2 (es)
KR (1) KR20200138288A (es)
CN (1) CN112119098A (es)
AU (1) AU2019243764A1 (es)
BR (1) BR112020019465A2 (es)
CA (1) CA3094827A1 (es)
IL (1) IL277573A (es)
MA (1) MA52238A (es)
MX (1) MX2020010110A (es)
PH (1) PH12020551556A1 (es)
SG (1) SG11202009308WA (es)
WO (1) WO2019189453A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020180110A (ja) * 2019-03-29 2020-11-05 田辺三菱製薬株式会社 ｃＭＥＴモノクローナル結合剤の薬物複合体を含む医薬組成物
CN111363042B (zh) * 2020-03-30 2022-02-11 中国人民解放军第四军医大学 一种高特异性抗小鼠cd226单克隆抗体及其应用
MX2023009146A (es) * 2021-02-03 2023-08-17 Mythic Therapeutics Inc Anticuerpos y usos de estos.
WO2022214517A1 (en) * 2021-04-08 2022-10-13 Byondis B.V. Anti-c-met antibodies and antibody-drug conjugates

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1981981T3 (da) * 2006-02-06 2011-09-26 Metheresis Translational Res Sa Monoklonalt anti-met antistof, fragmenter og vektorer deraf til behandling af tumorer, samt tilsvarende produkter
US7910702B2 (en) * 2006-07-28 2011-03-22 The Governors Of The University Of Alberta Recombinant antibodies to sclerotinia antigens
AR070861A1 (es) * 2008-03-06 2010-05-12 Genentech Inc Uso de terapia de combinacion con antagonistas de c-met y egfr
US20140161800A1 (en) * 2011-04-22 2014-06-12 John W. Blankenship Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods
US20150368329A1 (en) * 2012-10-15 2015-12-24 Oncomed Pharmaceuticals, Inc. Methods of Treating Ocular Diseases
GB201317982D0 (en) * 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
CN106488774B (zh) * 2014-04-18 2019-11-01 纽约州立大学研究基金会 人源化抗-tf-抗原抗体
BR112017005202A2 (pt) * 2014-09-16 2017-12-12 Symphogen As anticorpos anti-met e composições
US20170281796A1 (en) * 2014-12-08 2017-10-05 Sorrento Therapeutics, Inc. c-Met Antibody Drug Conjugate
US20180057595A1 (en) * 2015-03-16 2018-03-01 Celldex Therapeutics, Inc. Anti-MET Antibodies and Methods of Use Thereof
GB201602356D0 (en) * 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
PT3458102T (pt) * 2016-05-17 2020-08-17 Abbvie Inc Conjugados de fármacos com anticorpo anti-cmet e métodos para o seu uso
HUE054571T2 (hu) * 2016-09-14 2021-09-28 Merck Patent Gmbh Hatékony tumorgátlásra szolgáló C-MET elleni ellenanyagok és ellenanyag-drog konjugátumaik
CN116731177A (zh) * 2016-09-29 2023-09-12 田边三菱制药株式会社 cMET单克隆结合剂、其药物缀合物及其用途

Also Published As

Publication number Publication date
CA3094827A1 (en) 2019-10-03
IL277573A (en) 2020-11-30
KR20200138288A (ko) 2020-12-09
JP2021519319A (ja) 2021-08-10
PH12020551556A1 (en) 2021-06-07
SG11202009308WA (en) 2020-10-29
JP7490736B2 (ja) 2024-05-27
JP2023025034A (ja) 2023-02-21
US20210163604A1 (en) 2021-06-03
MA52238A (fr) 2021-02-17
RU2020135303A (ru) 2022-04-28
EP3774923A1 (en) 2021-02-17
EP3774923A4 (en) 2021-12-29
CN112119098A (zh) 2020-12-22
JP7177848B2 (ja) 2022-11-24
TW201946656A (zh) 2019-12-16
AU2019243764A1 (en) 2020-11-05
WO2019189453A1 (en) 2019-10-03
BR112020019465A2 (pt) 2021-01-12

Similar Documents

Publication Publication Date Title
PH12019502545A1 (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate
MX2019010804A (es) Compuestos de benzazepina, conjugados y usos de los mismos.
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
PH12020551556A1 (en) Drug conjugates of cmet monoclonal binding agents, and uses thereof
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
MX2020011546A (es) Anticuerpos anti-msr1 y metodos de uso de los mismos.
NZ748314A (en) Anti-cmet antibody drug conjugates and methods for their use
NZ752526A (en) Pyrrolobenzodiazepine conjugates
NZ741261A (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
MX2019001517A (es) Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer.
WO2017031458A3 (en) Anti-dll3 antibody drug conjugates and methods of use
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
EA201791203A1 (ru) ЛЕКАРСТВЕННЫЙ КОНЪЮГАТ АНТИТЕЛА ПРОТИВ с-МЕТ
MX2021015533A (es) Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
MX2019013753A (es) Combinaciones de inmunoconjugados anti-folr1 y anticuerpo anti-pd-1.
MA39909A (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
FR3096259B1 (fr) conjugués anticorps-médicament et leur utilisation en thérapie
AU2020380603A8 (en) Anti-mesothelin eribulin antibody-drug conjugates and methods of use
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
SA519401424B1 (ar) Cmet عوامل ربط أحادية النسيلة، مترافقات عقار منها واستخداماتها
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
MX2020002802A (es) Anticuerpos de cadena pesada que se unen a ectoenzimas.
MX2020010408A (es) Conjugados de anticuerpo-farmaco y sus usos para el tratamiento del cancer.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
MX2022001731A (es) Tratamiento de cánceres con conjugados anticuerpo-farmaco (adc) que se unen a las proteínas 191p4d12.